iPS Cells: A New Era of Medicine by Nobel Laureate Shinya Yamanaka

Added:

Genomic Instability, Oncogenic Risks, and Epigenetic Memory of iPSCs

While iPS cells (iPSCs) offer immense promise, significant biological and safety hurdles challenge their widespread clinical application. A major concern is tumorigenicity; the reprogramming process, especially when using oncogenes like c-Myc, can predispose these cells to forming teratomas or cancers. Furthermore, iPSCs often exhibit genomic instability, accumulating mutations and chromosomal aberrations during reprogramming and long-term culture. Another critical limitation is 'epigenetic memory,' where iPSCs retain molecular signatures of their donor tissue, biasing their differentiation potential and compromising their predictability. Consequently, some researchers argue that embryonic stem cells (ESCs) remain a more stable standard, or that direct reprogramming (transdifferentiation)—which converts mature cells directly into other adult cell types without passing through a pluripotent state—presents a safer, more efficient alternative for regenerative medicine.

Understanding the basic structure of human cells, DNA, and the process of gene expression and regulation.
The fundamental differences between somatic (body) cells and stem cells, including the concepts of cell differentiation and potency (totipotency, pluripotency, and multipotency).
The function of transcription factors in molecular biology and how they control the transfer of genetic information from DNA to RNA.
Basic historical context of regenerative medicine and early embryonic stem cell research, including the ethical debates surrounding them.
The specific molecular mechanism of reprogramming, focusing on the discovery and function of the four 'Yamanaka factors' (Oct3/4, Sox2, Klf4, and c-Myc).
Clinical applications of iPS cells in disease modeling (such as 'disease-in-a-dish' concepts) and high-throughput drug screening.
The use of patient-specific iPS cells in personalized medicine and autologous transplantation to avoid immune rejection.
Current challenges and safety concerns in iPSC therapies, including genomic instability, immunogenicity, and the risk of tumorigenesis (teratoma formation).
Advanced integration of iPS cell technology with CRISPR-Cas9 gene editing and the development of 3D organoids.
126.7K views2.6Klikes1:17:30@NobelPrizeIIOriginal Release: 2017-09-17

Induced pluripotent stem cells (iPSCs) are created by converting adult somatic cells (such as skin or blood cells) back to a pluripotent state using specific transcription factors (typically Oct3/4, Sox2, Klf4, and c-Myc), enabling unlimited expansion and differentiation into any cell type for regenerative medicine and drug development applications.